By Stuart Condie

SYDNEY--Fisher & Paykel Healthcare Corp.'s operating revenue for the first nine months of FY 2021 was 73% higher than in the same period a year earlier due to surging coronavirus-driven demand.

The New Zealand-based medical device manufacturer on Friday said the rise, which strips out the impact of currency movements, was driven by strong hardware sales and use amid elevated hospitalization rates.

It said operating revenue from hospital products, which includes those used in acute and chronic respiratory care and surgery, grew 113% on-year. Hospital hardware operating revenue grew 446% and hospital consumables grew 54%, both in constant currency, it added.

Fisher & Paykel declined to give formal FY 2021 guidance due to continued uncertainty over the spread of Covid-19 and the impact of vaccine roll-outs.

Write to Stuart Condie at stuart.condie@wsj.com

(END) Dow Jones Newswires

01-21-21 1637ET